Shares of Capricor Therapeutics (NASDAQ: CAPR) plunged about 65% on July 27 after FDA briefing documents raised fresh doubts about whether Deramiocel has sufficient evidence to win approval for Duchenne muscular dystrophy-related cardiomyopathy.
The FDA is preparing for a July 29 meeting of its Cellular, Tissue, and Gene Therapies Advisory Committee. The panel will evaluate Deramiocel, an investigational cell therapy made from donor heart tissue, for cardiomyopathy in male patients with Duchenne muscular dystrophy.
The committee’s recommendation will not determine whether Deramiocel is approved. Advisory committee votes are nonbinding, and the FDA will make the final regulatory decision separately. The agency has set August 22, 2026, as the PDUFA target action date for the resubmitted application.
According to Reuters, FDA staff also questioned changes to the endpoint analysis and whether trial participants had sufficiently documented DMD-related cardiomyopathy. If some participants were not clearly shown to have the condition, their results may provide weaker evidence for the specific cardiomyopathy indication Capricor is seeking.
FDA Concerns Put Deramiocel Under Pressure
The regulatory dispute centers on whether Phase 3 HOPE 3 provides substantial evidence that Deramiocel is effective for DMD-related cardiomyopathy.
Specifically, FDA reviewers said HOPE 3 did not achieve statistical significance for its primary and secondary efficacy endpoints when analyzed using the methodology the agency identified as prespecified. Prespecified endpoints and analytical methods are generally established before researchers evaluate unblinded trial results.
Capricor, however, argues that analyses conducted under its revised statistical plan showed a statistically significant benefit on the Performance of the Upper Limb 2.0, or PUL 2.0, measure. The company says the revised plan was finalized before the trial was unblinded.
The distinction is important. Using the methodology FDA reviewers consider prespecified, the trial did not meet its efficacy endpoints. Capricor’s statistically significant PUL 2.0 result emerged from a different analytical approach that the company says it established before unblinding. FDA reviewers have therefore questioned whether the methodological changes were adequately justified and consistently applied.
PUL 2.0 evaluates upper-limb function rather than cardiac performance. Capricor is presenting the upper-limb results as part of the overall evidence supporting Deramiocel, alongside separate cardiac measurements.
FDA reviewers also objected to changes in the analysis of left ventricular ejection fraction, or LVEF, the trial’s key cardiac endpoint. The revised approach ranked patient outcomes rather than directly comparing changes in the percentage of blood pumped by the heart, creating another dispute over whether HOPE 3 demonstrated a reliable cardiac benefit.
In effect, Capricor is asking the FDA to assess the combined pattern of functional and cardiac findings in evaluating the application. The FDA must determine whether that combined evidence is sufficient to support a cardiomyopathy indication, particularly since PUL 2.0 does not directly measure cardiac function.
A separate dispute concerns which version of Capricor’s statistical analysis plan the FDA should have evaluated.
Capricor said it submitted an updated statistical analysis plan to the FDA in September 2025 but received no feedback. The company says its final plan, SAP version 3.0, was completed before the trial was unblinded. It has challenged the FDA review, arguing that the agency’s briefing materials relied on SAP version 1.1, which Capricor describes as an incomplete earlier draft.
FDA reviewers responded that the September 2025 submission was not the final statistical plan ultimately used for the BLA resubmission. According to reviewers, the final version had not been submitted for advance agency review, and some analyses included in the clinical study report deviated further from that plan.
Capricor therefore maintains that the agency evaluated the application using an incomplete earlier version of its statistical approach, despite the company finalizing its later plan before unblinding. FDA reviewers, however, remain concerned that the final methodology was neither reviewed in advance nor applied consistently in the resubmitted analyses.
The stakes are high. Capricor previously received a Complete Response Letter, meaning the FDA declined to approve the application in its existing form. The agency said the application lacked substantial evidence of effectiveness while identifying chemistry, manufacturing, and controls (CMC) deficiencies. Capricor said some CMC materials submitted late in the review cycle were not evaluated before the letter was issued.
The FDA subsequently accepted Capricor’s response as a complete Class 2 resubmission and resumed its full review of the application, resulting in the new August 22 PDUFA target action date.
Why CAPR Stock Plunged on Monday
The immediate catalyst was the FDA briefing material released ahead of the July 29 advisory committee meeting.
The documents forced investors to reassess the probability that Deramiocel will ultimately receive approval. Because the therapy represents Capricor’s principal near-term commercial opportunity, a lower perceived chance of approval directly reduces expectations for future revenue, planned manufacturing expansion, and the company’s overall valuation.
The previous Complete Response Letter makes the latest FDA criticism particularly important. Investors had been counting on the resubmission and revised HOPE 3 analysis to address the agency’s earlier concerns. The briefing documents instead indicated that significant disagreements over efficacy, endpoint selection, and statistical methodology remain unresolved.
Capricor’s Commercial Plans Depend on FDA Approval
The regulatory uncertainty also affects commitments Capricor has made in preparation for a potential commercial launch.
Capricor recently signed a lease for approximately 171,000 square feet in San Diego to expand its manufacturing cleanrooms, research facilities, and office space. Subject to the lease terms, either party may terminate the agreement by providing notice within five business days after December 31, 2026, if Deramiocel has not received FDA approval by that date.
The stated initial monthly base rent is approximately $958,000, with 3.0% annual increases. However, rent does not commence until 12 months after the lease begins. Capricor will then receive 18 months of full base-rent abatement, followed by six months of partial abatement.
In practical terms, Capricor will not begin paying the full stated base rent immediately because the agreement includes both a delayed rent commencement and extended abatement periods.
The lease reflects Capricor’s preparations for potential commercialization while giving the parties an exit mechanism if Deramiocel is not approved by the specified deadline. Approval could support the company’s planned manufacturing expansion, while another regulatory setback could delay commercialization and materially weaken the investment case.
The bullish case remains tied to approval and successful commercialization. A Simply Wall St investment narrative projects that Capricor could generate $245.5 million in revenue and $109.6 million in earnings by 2029. The figures are not company guidance and are based on analyst forecasts incorporated into the platform’s investment narrative. They depend heavily on Deramiocel securing approval and achieving commercial adoption.
The July 29 meeting is therefore shaping up to be a defining catalyst for CAPR. The committee’s assessment could materially change investors’ view of Deramiocel’s approval prospects and Capricor’s commercial future. However, its recommendation will be nonbinding, and the FDA will make the final approval decision separately, with August 22, 2026, set as the PDUFA target action date.
